Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
People travel for many reasons, including tourism, business, educational experiences, or to flee from war, famine, or other intolerable situations. In 2019, international tourist arrivals reached 1.4 billion and were predicted by The World Tourism Organization to exceed 1.8 billion by 2030 before the COVID pandemic halted a 9-year trend of sustained growth in tourism. International migrants, a category of traveler not captured in the tourism statistics, included more than 270 million refugees, asylum seekers, migrant workers, illegal migrants, and internally displaced persons in 2019.
Despite the global COVID-19 pandemic, it is likely that when international travel resumes, many health providers will be called on to offer advice about pretravel immunizations. Although travel clinics specializing in pretravel health advice and immunization are present in many locations, most travelers will not be seen in these clinics before travel. Health professionals of all kinds must be able to provide basic pretravel services and identify patients in need of specialized advice. This chapter focuses on disease risks specific to travelers and considerations taken into consideration when deciding what vaccines are indicated for the trip. Information about disease epidemiology and vaccine characteristics is presented in detail in other chapters. Because national standards for licensure differ, not all vaccines are available in all countries, and vaccines against the same disease and recommended vaccine schedules may differ somewhat by manufacturer and national authority.
The two steps in immunizing travelers are to assess and if necessary update routine immunizations and provide travel-specific immunizations. To do the first, knowledge of a patient's previous immunizations and medical history is necessary. For the second, detailed information about the patient's itinerary, living conditions during travel, mode of travel (e.g., adventure travel or chaperoned luxury tour), and purpose of travel (e.g., medical or veterinary work, tourism, visiting relatives) is needed. Although sometimes mistakenly regarded as a rote selection of vaccines based on destination country, choice of vaccines more often requires thoughtful consideration of the patient's medical history, interactions of vaccines with other vaccines or medications, limitations posed by time until departure, magnitude of risk of vaccine-preventable diseases, and patient preferences. Cost is a factor in a traveler's decision-making process about which vaccines to receive and which family members to protect—limitations force priorities. Gradient of risk during the voyage needs to be considered. Travelers are originating from countries previously considered only as destination countries, leading to situations in which risk of disease is lower in the destination country, for example, the risk of acquiring typhoid for someone originating in Kolkata, India, who plans to visit relatives in East Africa is likely to be lower than at home. Finally, the journey itself may engender unanticipated health risks beyond the destination itself, as witnessed by the transmission of SARS-CoV-2 during tranvel.
Sources of health information for international travel include International Travel and Health-Vaccination Requirements and Health Advice; while the print edition has not been available since 2012, electronic updates, especially of the vaccine chapter, are available through the World Health Organization (WHO) The National Travel Health Network and Centre (NaTHNaC) at: https://travelhealthpro.org.uk/ , Health Information for International Travel (Yellow Book), published by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, and available at the CDC travel health website ( https://wwwnc.cdc.gov/travel ), Immunisation for Travel ( https://www.health.gov.au/health-topics/immunisation/immunisation-throughout-life/immunisation-for-travel ) and other local and national resources. Many countries publish national guidelines regarding travel health information, and readers are encouraged to base their recommendations on those. Other sources of information are textbooks , and review articles. The International Society of Travel Medicine, founded in 1991, promotes healthy and safe travel through education, service, and research; its biannual Conference is the largest and most elaborate opportunity for continued education in the field. Many sites on the Internet provide travel health information for health providers and the public, although not all are reliable.
The CDC publishes downloadable vaccine information statements for vaccines available in the United States. These handouts are useful when discussing with patients risk of disease, indications and contraindications for vaccine, adverse events associated with vaccines, and need for and timing of booster doses. Detailed technical recommendations of the Advisory Committee on Immunization Practices (ACIP) for many travel-related vaccines are also available. Comprehensive information on each vaccine can be found in individual chapters in this textbook.
Scheduling multiple vaccines for the traveler can be challenging, especially when departures are imminent. Although scheduling a consultation at least 4–6 weeks before travel is ideal, few travelers allow as long as a month, and many come for consultation only a few days before departure. Whenever the traveler is seen, there is potential for helpful information to be given, and some agents (e.g., hepatitis A vaccine, influenza vaccine when available, updates on routine vaccines), can be given with good effectiveness even on the day of departure. Immunization schedules can be accelerated, or vaccines limited to those most appropriate to the infectious disease risks likely to be faced by the traveler. Although many patients and providers are concerned about the likelihood of adverse reactions to multiple vaccines administered simultaneously, studies performed in travel clinics that evaluated simultaneous administration of multiple vaccines, including travel vaccines, reported that adverse events were generally minor and not incapacitating. , The ACIP encourages simultaneous administration of all needed vaccines.
Non-live vaccines can be given concurrently or at any interval before or after other non-live or live vaccines (see Chapter 10 ). https://www.cdc.gov/vaccines/covid-19/hcp/faq.html . Live vaccines [such as yellow fever, measles–mumps–rubella (MMR), and varicella] should be administered either simultaneously or at least 28 days apart. When live vaccines are given less than 28 days apart, the second should not be counted as valid and should be repeated at least 28 days from the first administration. Some data exist to support exceptions: oral poliovirus vaccine (OPV), no longer used in many countries, may be given at any interval before or after parenteral live vaccines; yellow fever vaccine may be given at any interval with respect to monovalent measles vaccine; and Ty21a oral typhoid vaccine may be given at the same time as or at any interval relative to parenteral live vaccines (MMR, varicella, yellow fever). ,
Antibody responses to MMR and varicella vaccines may be impaired if given at the same time as immunoglobulin. MMR and varicella vaccines should be administered at least 2 weeks before immunoglobulin, although they can be administered at the same time, if necessary. If immunoglobulin is given before MMR or varicella vaccines, the appropriate time interval after immunoglobulin for giving these vaccines depends on the dose of immunoglobulin administered; a helpful table detailing appropriate intervals is available. Immunoglobulin has not been shown to interfere with responses to polio, yellow fever, or oral typhoid vaccines.
Detailed recommendations regarding immunization of immunocompromised persons are published elsewhere (see Chapter 70 ) and are available from the CDC and from the Infectious Diseases Society of America. , Information specific to immunocompromised travelers is available from the CDC. In general, immunocompromised persons should not receive live viral vaccines, but there may be some exceptions. Information specific to travel vaccines is presented in the sections on individual vaccines below.
When antimalarials in the chloroquine/mefloquine family are administered simultaneously with human diploid cell rabies vaccines, they may interfere with immunogenicity of the vaccines. It does not appear that these antimalarials interfere with immunogenicity of the oral typhoid vaccine. The combination of antimicrobial agents and oral typhoid or cholera vaccines is contraindicated because they would probably interfere with the activity of these live bacterial vaccines. Details of these interactions can be found in the sections devoted to individual vaccines below.
Routine childhood and adult immunizations should be brought up to date as part of the preparation for international travel. Information is available from many sources about routine immunizations; many countries update their immunization plan every year. In the United States, schedules are available from the CDC on the Internet ( https://www.cdc.gov/vaccines/acip/recommendations.html ). Readers are also referred to country-specific schedules for this information. Some travelers will require accelerated schedules because of imminent departure dates or because of immunization delays. The reader is referred to Chapter 10 and Chapter 74 for routine and accelerated schedules in the United States and to the chapters on individual vaccines for detailed information. Children in the United States are immunized routinely against 16 diseases ( Table 71.1 ). Most diseases for which children are immunized routinely are present worldwide, although the risk of contracting them varies markedly depending on the travel destination. Additional information about adult immunization is available. Indications specific to travel are given in sections referring to individual vaccines below. All adults should be up to date with routine childhood immunizations, and all (who have no contraindication) in the United States should receive annual influenza vaccination; influenza immunization is recommended from age 60 or 65 years in some countries, although the risk of influenza is worldwide. Those 65 years of age or older, or at any age with certain medical conditions, should be immunized against pneumococcal disease. Older adults without contraindications should be considered for zoster vaccine; the age at which it is given varies by country (e.g., 50s in the United States, 70s in the UK, etc.).
Disease | Vaccine | Age Groups | Greatest Areas of Risk | Special Indications |
Diphtheria | DTaP or DTP | <7 y | India and many other countries in the developing world | |
Td | ≥7 y | |||
Tdap | ≥11 y | Tdap may be given to those age 7–10 y who are not fully immunized against pertussis; may be used as booster dose for all ages | ||
Tetanus | DTaP or DTP | <7 y | Worldwide | |
Td | ≥7 y | |||
Tdap | ≥11 y | May be used as booster dose for all ages | ||
Pertussis | DTaP or DTP Tdap | <7 y ≥11 y | Worldwide circulation | Tdap may be given to those age 7–10 y who are not fully immunized against pertussis; Tdap may be used as booster dose for all ages |
Polio | IPV | <18 y and previously unvaccinated adults | Pakistan, Afghanistan, also many countries in Africa for risk of cVDPV | Extra dose of IPV (if previously fully immunized) for persons traveling to areas of risk |
Measles | MMR, MR, MMRV, or M b | All ages for susceptible persons | Worldwide | 2 Doses separated by ≥28 days for those age ≥12 mo; first dose may be given as early as age 6 mo but should not be counted toward the routine 2 dose series; most persons born in the US before 1957 can be considered immune and do not need vaccination |
Mumps | MMR, MMRV, Mu b | All ages for susceptible persons | Worldwide | |
Rubella | MMR, MMRV, MR, or R b | All ages for susceptible persons | Worldwide | Especially for nonpregnant females of childbearing age |
Haemophilus influenzae type b | Hib | <5 y | Most of the world | |
Hepatitis A | Hep A | Children 1–17 years | Developing world | All ages for susceptible persons. Children traveling for the purpose of visiting friends or relatives may be at greater risk; first dose may be given as early as age 6 mo but should not be counted toward the routine 2 dose series |
Hepatitis B | Hep B | Birth to 59 years; older ages with special risk | Most of the world; see Fig. 71.1 | Travel to areas with hepatitis B prevalence ≥2%; occupational or behavioral risk factors for disease |
Pneumococcal | Pneumococcal conjugate | All children under age 5; adults with certain medical conditions adults age ≥65 y | Worldwide | |
Pneumococcal a | Pneumococcal polysaccharide | Children 2–18 years with certain medical conditions; adults who receive PCV | Worldwide | |
Varicella | Varicella or MMRV | All ages for susceptible persons | Most of the world | |
Influenza a | Influenza | 1 Dose annually in persons age ≥6 mo; 2 doses for the first influenza season for children age <9 y | Seasonal, except for tropics all year | Northern hemisphere December through March; southern hemisphere April through September |
Human papillomavirus | HPV | 9- to 26-y-old | Worldwide | |
Meningococcal | Conjugate ACYW135 | 1 Dose for 11- to 12-y-olds; with booster at 16 y; adolescents at high school entry; college students | Meningitis belt in sub-Saharan Africa, mass gatherings | Travelers to high-risk areas |
Meningococcal B | Serogroup B | >10 y-old at increased risk for meningococcal disease | Worldwide | |
Rotavirus | Rotavirus | All children age 6–32 wk | Worldwide |
a Vaccines routinely indicated for adults.
b Single antigen measles, mumps, and rubella vaccines are no longer available in the United States. DTaP, diphtheria and tetanus toxoids and acellular pertussis; DTP, diphtheria and tetanus toxoids and pertussis; Hep A, hepatitis A; Hep B, hepatitis B; Hib, Haemophilus influenzae type b; HPV human papillomavirus; IPV, inactivated poliovirus vaccine; M, measles; MMR, measles-mumps-rubella; MR, measles-rubella; Mu, mumps; Td, tetanus and diphtheria toxoids; Tdap, tetanus toxoid, diphtheria toxoid, and acellular pertussis; R, rubella. The most current ACIP recommended adult and childhood vaccination schedules can be found at www.cdc.gov/vaccines/schedules/hcp/ .
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here